EMA Application withdrawn: Sliwens — Sanofi Aventis

View source ↗

Summary

The EMA withdrew the application for Sliwens by Sanofi Aventis in the sleep initiation and maintenance disorders therapeutic area.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sleep Initiation and Maintenance Disorders

Drugs mentioned

• Sliwens (eplivanserin)

Snippet

Status: Application withdrawn. Therapeutic area: Sleep Initiation and Maintenance Disorders. MAH: Sanofi Aventis. Decision date: 31/12/2009